Buprenorphine Implementation at Syringe Service Programs to Reduce Overdoses
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is testing whether offering buprenorphine treatment directly at syringe service programs (SSPs) helps more people start and stay in treatment for opioid use disorder (OUD) than referring them to community buprenorphine treatment providers. Buprenorphine is a medication that helps reduce opioid cravings and withdrawal symptoms. The study compares two ways of connecting people to treatment: Referral to a community treatment provider (usual care before the new program begins). Onsite, low-threshold buprenorphine treatment at the SSP, which allows participants to start medication quickly and without having to establish care at another provider. Participants will be adults who have opioid use disorder and are SSP clients. Each SSP will begin offering the new onsite buprenorphine program at different times during the study. Researchers will collect information before and after the new program begins to see how it affects treatment engagement and health outcomes. The study will also examine how easy or difficult it is for SSPs to start and run the new program, how acceptable it is to staff and participants, and whether it is cost-effective. The overall goal is to find better ways to expand access to life-saving opioid treatment in community-based settings.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Rozpoznanie umiarkowanego lub ciężkiego uzależnienia od opioidów
- •Chęć przyjmowania leczenia bupremorfiną
- •Mówienie po angielsku lub hiszpańsku
- •Aktualny klient centrum wymiany igieł
- •Zdolność do wyrażenia świadomej zgody na udział
✗ Disqualifies
- •Aktualnie otrzymywanie innego leczenia opioidowego na receptę
- •Niestabilne problemy psychiczne lub zdrowotne wymagające natychmiastowej opieki medycznej
- •Alergia na bupremorfnę
- •Przebywanie w areszcie, więzieniu lub innym zamkniętym ośrodku przez wyrok sądu albo oczekiwanie na rozprawę mogące uniemożliwić udział
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 21, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (8)
Community Health Project Los Angeles (CHPLA)
Los Angeles, United States
HIPS
Washington D.C., United States
CARPBR/Be Safe Syringe Program
Baton Rouge, United States
Harm Reduction Sisters
Duluth, United States
Alianza of New Mexico
Roswell, United States
HIV Alliance
Grants Pass, United States
Challenges, Inc/Prisma Health
Greenville, United States
Vivent Health
Milwaukee, United States
Trial contact
Megan M Ghiroli
Aaron D Fox, MD, MS
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/22/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.